1143575-95-4

Usage

Uses

Used in Pharmaceutical Synthesis:
(3-Methoxy-2-nitro-phenyl)-methyl-amine is utilized as a key intermediate in the synthesis of various pharmaceutical products. Its unique chemical structure, featuring a nitro and methoxy group on a phenyl ring, allows for the development of new drugs with specific therapeutic properties.
Used in Organic Chemistry as a Reagent:
In the field of organic chemistry, (3-Methoxy-2-nitro-phenyl)-methyl-amine serves as a valuable reagent for various chemical reactions. Its functional groups enable it to participate in a range of reactions, such as nucleophilic substitution, reductive amination, and cross-coupling reactions, contributing to the synthesis of diverse organic compounds.
Used in Research and Development:
(3-Methoxy-2-nitro-phenyl)-methyl-amine is also employed in research and development for the discovery of new chemical entities and the optimization of existing synthetic routes. Its unique structural features make it a promising candidate for the exploration of novel chemical reactions and the development of innovative synthetic strategies.

Upstream product

• 158461-29-1 tert-butyl N-(2-nitro-3-methoxyphenyl)carbamate 
• 4920-80-3 3-methoxy-2-nitrobenzoic acid 
• 1143575-94-3 tert-butyl (3-methoxy-2-nitrophenyl)-(methyl)carbamate 
• 641-49-6 1-fluoro-3-methoxy-2-nitrobenzene 
• 74-89-5 methylamine 

Downstream Products

• 177477-60-0 3-methoxy-N₁-methylbenzene-1,2-diamine 
• 33604-87-4 2-chloro-4-methoxy-1-methyl-1H-benzimidazole 

Relevant academic research and scientific papers

COMBINATIONS OF MEDICAMENTS, CONTAINING PDE4-INHIBITORS AND EP4-RECEPTOR-ANTAGONISTS

The present invention relates to new medicament combinations which contain in addition to one or more PDE4-inhibitors (1) at least one EP4 receptor antagonist (2), as well as the use thereof for the treatment of preferably respiratory complaints such as particularly COPD, chronic sinusitis and asthma. The invention relates in particular to those medicament combinations which contain at least one EP4 receptor antagonist (2), in addition to one or more, preferably one, PDE4 inhibitor of general formula 1 wherein X is SO or SO2, but preferably SO, and wherein R3 denotes an optionally substituted, mono- or bicyclic, unsaturated, partly saturated or saturated heterocyclic group or an optionally substituted, mono- or bicyclic heteroaryland wherein R1 and R2 have the meanings given in claim 1, the preparation thereof and the use thereof for the treatment of respiratory complaints.

BENZOXAZINONE DERIVATIVES FOR THE TREATMENT OF GLYTL MEDIATED DISORDERS

The present invention relates to benzoxazinone derivatives, processes for their preparation, pharmaceutical compositions and medicaments containing them and to their use in treating disorders mediated by GlyT1, including neurological and neuropsychiatric disorders, in particular psychoses, dementia or attention deficit disorder.

HETEROCYCLE-SUBSTITUTED PIPERAZINO-DIHYDROTHIENOPYRIMIDINES

The invention relates to new dihydrothienopyrimidinesulphoxides of formula 1, as well as pharmacologically acceptable salts thereof, wherein X is SO or SO2, but preferably SO, and wherein R3 denotes an optionally substituted, mono- or bicyclic, unsaturated, partially saturated or saturated heterocycle or an optionally substituted, mono- or bicyclic heteroaryl and wherein R1 and R2 have the meanings stated in claim 1, as well as pharmaceutical compositions which contain these compounds. These new dihydrothienopyrimidinesulphoxides are suitable for the treatment of respiratory or gastrointestinal complaints or diseases, inflammatory diseases of the joints, skin or eyes, diseases of the peripheral or central nervous system or cancers.

QUINOXALINEDIONE DERIVATIVES

The present invention relates to compounds of formula (I) wherein X, Y, Z, R1, R2, R3 are as defined in claim 1, including pharmaceutical compositions thereof and for their use in the treatment and/or prevention of diabete